Interestingly, Ang-(1–7) treatment in Ang II-treated animals inhibited ERK1/2/NF-κB axis, proinflammatory cascade and ameliorated lung fibrosis, effects that were reverse by Mas antagonists. The gene discussed is MAPK3; the disease is pulmonary fibrosis.